Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2557007 | 0.82 | GAA (0.42) | CHRNB2CHRNA4 | |
| SCHEMBL28967087 | 0.82 | ENPP2 (0.36) | ENPP2TTR | |
| SCHEMBL13651757 | 0.73 | ENPP2 (0.44) | ENPP2TTRCHRNB2CHRNA4 | |
| SCHEMBL29538949 | 0.73 | HCAR2 (0.45) | HCAR2ENPP2 | |
| SCHEMBL29957005 | 0.73 | ENPP2 (0.44) | ENPP2TTRCHRNB2CHRNA4 | |
| SCHEMBL27969 | 0.73 | HCAR2 (0.45) | HCAR2ENPP2 | |
| SCHEMBL25098761 | 0.73 | CHRNB2 (0.35) | HCAR2CHRNB2CHRNA4 | |
| SCHEMBL197638 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL16899234 | 0.71 | ENPP2 (0.43) | ENPP2TTRCHRNB2CHRNA4 | |
| SCHEMBL144194 | 0.71 | HCAR2 (0.43) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 699 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116559-A | Pyridine urea compound and preparation method and pharmaceutical application thereof | 复旦大学 | 2020-05-08 | — | — | CN | claimed |
| US-9156834-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2015-10-13 | — | — | US | claimed |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PF MEDICAMENT (FR) | 2014-12-04 | — | — | US | claimed |
| US-8846930-B2 | Derivatives of heteroarylsulfonamides, their preparation and their application in human therapy | PIERRE FABRE MEDICAMENT (FR) | 2014-09-30 | — | — | US | claimed |
| EP-2643318-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | Pierre Fabre Médicament (FR) | 2013-10-02 | — | — | EP | claimed |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2013-07-04 | — | — | US | claimed |
| WO-2012069503-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | PIERRE FABRE MEDICAMENT (FR) | 2012-05-31 | — | — | WO | claimed |
| US-20260125392-A1 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SHIONOGI & CO., LTD. (JP) | 2026-05-07 | — | — | US | disclosed |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | GENENTECH, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| EP-4568746-B1 | BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2026-04-29 | — | — | EP | disclosed |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12545687-B2 | Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SHIONOGI & CO., LTD. (JP) | 2026-02-10 | — | — | US | disclosed |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-16 | — | — | US | disclosed |
| WO-2009074246-A1 | NOVEL 2-HETARYL THIAZOLE-4-CARBOXAMIDE DERIVATIVES, PRODUCTION THEREOF, AND USE THEREOF AS A MEDICAMENT | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| EP-2070924-A1 | New 2 hetarylthiazol-4-carboxylic acid derivatives, their manufacture and use as medicine | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| US-20080161269-A1 | Compounds 620 | ASTRAZENECA AB (SE) | 2008-07-03 | — | — | US | disclosed |
| US-5629428-A | 3-Chloropyridines, and their use in liquid-crystal mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161269-A1 | Compounds 620 | MAPT, PSEN1, PSEN2 | HCAR2 1487/4885ENPP2 3174/4885MKNK1 437/4885 |
| US-20080176862-A1 | Cognitive impairment, Alzheimer disease, neurodegeneration, dementia; such as 3'-(2-amino-4-(2-chloropyridin-4-yl)-1-methyl-5-oxo-4,5-dihydro-1H-imidazol-4-yl)-5-chlorobiphenyl-3-yl methanesulfonate; Beta site APP Cleaving Enzyme (BACE) inhibitors | BACE1, BACE2, PSEN1 | HCAR2 3311/4885ENPP2 3267/4885MKNK1 763/4885 |
| US-20260125392-A1 | URACIL DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | SARS1, ACE, RNGTT | HCAR2 4567/4885ENPP2 4801/4885MKNK1 3775/4885 |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, CBR1, CNR1 | HCAR2 10/4885ENPP2 2252/4885MKNK1 3789/4885 |
| US-20130172326-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | HCAR2 653/4885ENPP2 3252/4885MKNK1 1732/4885 |
| US-12617802-B2 | Sulfonimidamide compounds as NLRP3 modulators | NLRP3, NLRP1, PYCARD | HCAR2 463/4885ENPP2 4253/4885MKNK1 2425/4885 |
| US-20140357624-A1 | DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY | KCNA4, KCNA1, KCNB1 | HCAR2 653/4885ENPP2 3252/4885MKNK1 1732/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | HCAR2 374/4885ENPP2 34/4885MKNK1 3311/4885 |
| US-20090182013-A1 | Derivatives of 5-Thioxylopyranose and Use of Same for Treatment | TPMT, PNPO, PPOX | HCAR2 3232/4885ENPP2 545/4885MKNK1 3785/4885 |
| US-12545687-B2 | Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same | SARS1, ACE, ACE2 | HCAR2 3842/4885ENPP2 4653/4885MKNK1 3011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.